Answers are grounded in this paper and cite their sources.
Haemorrhagic stroke causes a disproportionate share of stroke deaths and disability, and its incidence rises steeply with age. Vagus nerve stimulation (VNS) targets modifiable secondary injury processes, including neuroinflammation, cerebral oedema, autonomic dysfunction and vasospasm, but its therapeutic role is uncertain. Animal studies and clinical randomised trials of VNS in intracerebral haemorrhage (ICH) or subarachnoid haemorrhage (SAH) were identified from Ovid MEDLINE (to 1 June 2026); appraised using SYRCLE, PEDro, and RoB 2; and synthesised narratively by level of evidence and pathology. Favourable functional outcome (modified Rankin Scale, 0–2) in SAH trials was pooled by random-effects meta-analysis. Nine reports were included: four preclinical (179 animals; three ICH models, one SAH model) and five clinical (four independent cohorts; 105 participants with haemorrhagic stroke: 97 SAH, 8 ICH). Animal studies reported reduced inflammatory signalling, haematoma volume and aneurysm rupture, as well as improved survival and motor recovery, with weaker effects after severe injury. In SAH trials, non-invasive VNS was feasible and well tolerated, with signals of reduced tumour necrosis factor-α and interleukin-6, less radiographic vasospasm and delayed cerebral ischaemia, and increased parasympathetic activity. The pooled functional outcome did not differ significantly (three trials: odds ratio [OR] 1.87, 95% confidence interval [CI] 0.65–5.37). Clinical ICH data were limited to 24 h safety in eight participants. VNS is biologically active and feasible but unproven; adequately powered, severity-stratified multicentre trials with standardised protocols and age-appropriate outcomes are needed.
No takes yet. Share an insight, caveat, or question.
Tupper et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: